Pfadnavigation Startseite Press Releases media Press Releases Subscribe to our press releases 2024 16/10/2024 Olivier Falut appointed EUROAPI’s Chief Financial Officer 15/10/2024 EUROAPI closes the financing of its FOCUS-27 plan 10/10/2024 EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution 05/08/2024 Availability of H1-24 Financial Report 30/07/2024 H1 2024 Results 26/06/2024 EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth 18/06/2024 EUROAPI and Priothera enter into CDMO collaboration to advance oncology project 06/06/2024 Market update - FOCUS-27 transformation project financing 06/06/2024 EUROAPI reaches major Health IPCEI milestone with official notification from European Commission 23/05/2024 EUROAPI strengthens its presence in animal health with a €130-150 million supply contract 22/05/2024 Combined General Meeting of May 22, 2024 13/05/2024 Evelyne Nguyen appointed EUROAPI’s Chief Financial Officer 30/04/2024 Combined General Meeting of May 22, 2024 - Availability of preparatory documents 09/04/2024 EUROAPI streamlines its Executive Committee to improve focus and efficiency 05/04/2024 05-APRIL-2024 – EUROAPI Availability of the 2023 Universal Registration Document, including the Annual Financial Report 14/03/2024 Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy 28/02/2024 Full-Year 2023 results 25/01/2024 EUROAPI enhances its CDMO capabilities through a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO) 04/01/2024 EUROAPI strengthens its Executive Committee with the appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer 2023 28/11/2023 EUROAPI appoints new Executive Committee members 21/11/2023 CDMO: EUROAPI completes acquisition of Biano 30/10/2023 Information relating to the financial terms of the departure of the Chief Executive Officer 25/10/2023 EUROAPI announces new governance 24/10/2023 EUROAPI increases the resources allocated to the liquidity contract with Kepler Cheuvreux 09/10/2023 Full-Year 2023 outlook revised downwards Launch of a strategic review Mid-term perspectives suspended 29/08/2023 EUROAPI to acquire BianoGMP to strengthen its CDMO expertise in the high-growth oligonucleotide market 02/08/2023 Availability of H1-23 Financial Report_02AUG23 01/08/2023 EUROAPI H1 2023 Results 13/06/2023 Health sovereignty: EUROAPI supports the supply of essential medicines to France and Europe 25/10/2023 EUROAPI announces new governance 06/06/2023 EUROAPI to invest €50 million at its Budapest site to meet the growing demand for prostaglandins 11/05/2023 Combined General Meeting of May 11, 2023 10/05/2023 EUROAPI’s Board of Directors proposes Géraldine Leveau as Director 09/05/2023 EUROAPI and Novéal sign CDMO agreement to advance cosmetic projects 26/04/2023 Availability of the Amendment n°1 of the 2022 Universal Registration Document 14/04/2023 Availability of the 2022 Universal Registration Document, including the Annual Financial Report 08/03/2023 EUROAPI Full-Year 2022 Results_March 8 2023 31/01/2023 Progressive restart of prostaglandin production at Budapest site 11/01/2023 EUROAPI’s Board of Directors proposes Mattias Perjos as independent Director 09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France 2022 07/12/2022 EUROAPI updates its 2022 financial guidance 31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025 01/09/2022 Availability of 2022 Half-Year Financial Report 01/09/2022 EUROAPI 2022 Half-year results 22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022” 21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France 01/07/2022 Availability of EUROAPI’s 2021 half-year results 09/06/2022 EUROAPI joins the SBF 120 and CAC Mid 60 indices 03/06/2022 EUROAPI launches its first global employee share plan “EUROAPI Action 2022” 01/06/2022 EUROAPI implements a liquidity contract with Kepler Cheuvreux 30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles 06/05/2022 EUROAPI announces the success of its listing on Euronext Paris 03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met 01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022
26/06/2024 EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth
06/06/2024 EUROAPI reaches major Health IPCEI milestone with official notification from European Commission
05/04/2024 05-APRIL-2024 – EUROAPI Availability of the 2023 Universal Registration Document, including the Annual Financial Report
14/03/2024 Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy
25/01/2024 EUROAPI enhances its CDMO capabilities through a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO)
04/01/2024 EUROAPI strengthens its Executive Committee with the appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer
30/10/2023 Information relating to the financial terms of the departure of the Chief Executive Officer
09/10/2023 Full-Year 2023 outlook revised downwards Launch of a strategic review Mid-term perspectives suspended
29/08/2023 EUROAPI to acquire BianoGMP to strengthen its CDMO expertise in the high-growth oligonucleotide market
13/06/2023 Health sovereignty: EUROAPI supports the supply of essential medicines to France and Europe
06/06/2023 EUROAPI to invest €50 million at its Budapest site to meet the growing demand for prostaglandins
14/04/2023 Availability of the 2022 Universal Registration Document, including the Annual Financial Report
09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France
31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025
22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022”
21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France
30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles
03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met
01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022